Evidence map›Paper›PMID 38645842›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2024

[Relationship Between Tim-3 and Galectin-9 Expression Levels, Clinical Pathological Characteristics, and Prognosis in Patients After Radical Resection of Colorectal Cancer].

Yiran Zhang, Dan Deng, Wan Yin, Jun Luo, Jinxing Liu, Chenjian Xie, Xingli Ji, Li Ma, Li Zhang, Xiangen Xia and 3 more

Open access · greenAbstract readEnglish Abstract
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
  3. [Role of Galectin-9 and Sonic Hedgehog Expressions in the Early Diagnosis and Prognosis of Colorectal Cancer].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yiran Zhang( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Dan Deng( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Wan Yin( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Jun Luo( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Jinxing Liu( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Chenjian Xie( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Xingli Ji( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Li Ma( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Li Zhang( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Xiangen Xia( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Shengjun Cheng( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Anliang Huang( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Fan Yang( 611137) School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Chengdu University of Traditional Chinese Medicine · CNChengdu Fifth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Some colorectal cancer patients still face high recurrence rates and poor prognoses even after they have undergone the surgical treatment of radical resection. Identifying potential biochemical markers and therapeutic targets for the prognostic evaluation of patients undergoing radical resection of colorectal cancer is crucial for improving their clinical outcomes. Recently, it has been reported that the T cell immunoglobulin and mucin domain protein 3 (Tim-3) and its ligand galactose lectin 9 (galectin-9) play crucial roles in immune dysfunction caused by various tumors, such as colorectal cancer. However, their expressions, biological functions, and prognostic value in colorectal cancer are still unclear. This study aims to investigate the relationship between Tim-3 and galectin-9 expression levels and the clinicopathological characteristics and prognosis of patients undergoing radical resection of colorectal cancer. Methods: A total of 171 patients who underwent radical resection of colorectal cancer at Chengdu Fifth People's Hospital between February 2018 and March 2019 were selected. Immunohistochemistry was performed to assess the expression levels of Tim-3 and galectin-9 in the cancer tissue samples and the paracancerous tissue samples of the patients. The relationship between Tim-3 and galectin-9 expression levels and the baseline clinical parameters of the patients was analyzed accordingly. Kaplan-Meier analysis was performed to assess the association between Tim-3 and galectin-9 expression levels and the relapse-free survival (RFS) and the overall survival (OS) of colorectal cancer patients. Cox regression analysis was conducted to identify factors associated with adverse prognosis in the patients. Results: The immunohistochemical results showed that the high expression levels of Tim-3 and galectin-9 were observed in 70.18% (120/171) and 32.16% (55/171), respectively, of the colorectal cancer tissues, whereas the low expression levels were 29.82% (51/171) and 67.84% (116/171), respectively. Furthermore, the expression score of Tim-3 was significantly higher in colorectal cancer tissues than that in the paracancerous tissues, while the expression score of galectin-9 was lower than that in the paracancerous tissues ( Conclusion: Aberrant expression of Tim-3 and galectin-9 is observed in colorectal cancer tissues. High expression of Tim-3 and low expression of galectin-9 are closely associated with adverse clinico-pathological characteristics and prognosis. They are identified as independent influencing factors that may trigger adverse prognostic events in patients. These findings suggest that Tim-3 and galectin-9 have potential as new therapeutic targets and clinical indicators.

Indexed as

Colorectal NeoplasmsGalectinsHepatitis A Virus Cellular Receptor 2AgedBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisBiomarkers, TumorGalectinsHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2LGALS9 protein, humanClinicopathological characteristicsColorectal cancerGalactose lectin 9Prognosis assessmentT-cell immunoglobulin and mucin domain protein 3

Identifiers

PMID38645842
PMCPMC11026871
OpenAlexW4395009634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.